Virios Therapeutics, Inc.

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed d…

Biotechnology

US, Alpharetta [HQ]

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Outstanding & Floating

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. It's perfect to get a quick briefing regarding the shareholder structure of Virios Therapeutics, Inc.

Virios Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.

Beneficial Owners Beta

Beneficial owners hold at least 10% of the stocks outstanding. Palmy retrieves this information from the most reliable, audited format which presents the data, the proxy statement.

Soon Available - Stay Tuned